These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1908746)

  • 1. Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour.
    Maas RA; Van Weering DH; Dullens HF; Den Otter W
    Cancer Immunol Immunother; 1991; 33(6):389-94. PubMed ID: 1908746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological analysis of IL-2 induced regression of murine solid SL2-tumors.
    Maas RA; Dullens HF; Henk D; Van Weering J; De Mik HJ; Koten JW; Belger RJ; Den Otter W
    Biotherapy; 1993; 6(2):83-91. PubMed ID: 8104452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.
    Maas RA; Dullens HF; De Jong WH; Den Otter W
    Cancer Res; 1989 Dec; 49(24 Pt 1):7037-40. PubMed ID: 2582444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice.
    Maas RA; Becker MJ; Weimar IS; De Nooy JC; Dullens HF; Den Otter WD
    Immunobiology; 1993 Jul; 188(3):281-92. PubMed ID: 7901148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenon.
    Bernsen MR; Van Barlingen HJ; Van der Velden AW; Dullens HF; Den Otter W; Heintz AP
    Int J Cancer; 1993 May; 54(3):513-7. PubMed ID: 8509227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming of the antitumor response promotes efficacy of interleukin-2 therapy.
    Everse LA; Bernsen MR; Dullens HF; Den Otter W
    Cancer Immunol Immunother; 1997 Jun; 44(4):221-9. PubMed ID: 9222281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength.
    Fiszer-Maliszewska L; Den Otter W; Mordarski M
    Cancer Immunol Immunother; 1999 Feb; 47(6):307-14. PubMed ID: 10203060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tumor regression induced by low doses of interleukin-2.
    Maas RA; Dullens HF; Den Otter W
    In Vivo; 1991; 5(6):637-41. PubMed ID: 1810449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local interleukin 2 therapy is most effective against cancer when injected intratumourally.
    Jacobs JJ; Sparendam D; Den Otter W
    Cancer Immunol Immunother; 2005 Jul; 54(7):647-54. PubMed ID: 15685449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective immunotherapy with local low doses of interleukin-2.
    Den Otter W; Maas RA; Koten JW; Dullens HF; Bernsen M; Klein WR; Rutten VP; Steerenberg PA; Balemans L; Ruitenberg EJ
    In Vivo; 1991; 5(6):561-5. PubMed ID: 1810439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy.
    Baselmans AH; Koten JW; Battermann JJ; Van Dijk JE; Den Otter W
    Cancer Immunol Immunother; 2002 Nov; 51(9):492-8. PubMed ID: 12357320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with IL-2 and IL-12 inhibits tumour cell division in SL2 lymphoma.
    Masztalerz A; Van Luyn M; Werner N; Molema G; Everse LA; Otter WD
    Anticancer Res; 2004; 24(5A):2633-42. PubMed ID: 15517867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.
    Dullens HF; Schakenraad S; Oostdijk A; Vuist W; Van der Maas M; Den Otter W
    Cancer Immunol Immunother; 1986; 22(2):100-6. PubMed ID: 3487380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study.
    Everse LA; Renes IB; Jürgenliemk-Schulz IM; Rutgers DH; Bernsen MR; Dullens HF; Den Otter W; Battermann JJ
    Int J Cancer; 1997 Sep; 72(6):1003-7. PubMed ID: 9378533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
    Baral E; Nagy E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system.
    Characiejus D; Dullens HF; Den Otter W
    Cancer Immunol Immunother; 1990; 32(3):179-84. PubMed ID: 2289212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN; Williams RM; Benacerraf B
    Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting an anti-viral CD8+ T cell response to a growing tumor facilitates its rejection.
    Böhm W; Schirmbeck R; Reimann J
    Cancer Immunol Immunother; 1997 Jun; 44(4):230-8. PubMed ID: 9222282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
    Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
    J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.